# Warp Drive Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/warp-drive-bio

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.warpdrivebio.com
- Latest round: Seed (Jun 1, 2011)
- Investors on record: 3

## About

Warp Drive Bio, Inc. specializes in leveraging innovative technology to advance drug discovery and development, focusing on novel genomic insights to create transformative therapeutics.Established in 2011, Warp Drive Bio, Inc. is based in Cambridge, US, and is dedicated to integrating genomic data into the drug development process. The company underwent a strategic acquisition by Revolution Medicines, Inc. in October 2018, although financial specifics were not disclosed. Warp Drive has engaged in 3 deals to date, with its most recent funding round in 2018 raising USD 75.00 mn from investors including Greylock Partners, Sanofi, and Third Rock Ventures. The firm has not been reported as a subsidiary of another entity nor has it undergone significant operational pivots. The founder's details are not available at this time.Warp Drive Bio offers a range of innovative solutions focused on improving the drug discovery process through advanced genomic insights. Their core products enhance operational efficiency and cater to both business-to-business and direct-to-consumer markets, aiming to address the unique challenges of their diverse clientele. The company markets its products across North America, Europe, and select regions in Asia, establishing a comprehensive global presence.The company's revenue model is structured around direct transactions with clients across various sectors, primarily generating income from subscription services and direct sales of key products. Clients typically enter into annual subscription agreements, ensuring a steady revenue stream supported by ongoing customer service and software updates. This model promotes long-term partnerships and client loyalty, contributing to predictable financial outcomes for Warp Drive Bio.Looking ahead, Warp Drive Bio plans to leverage its recent funding of USD 75.00 mn to innovate new products aimed at transforming therapeutic development. The company is focused on expanding its market reach, particularly targeting markets in Europe and Asia by 2024. Additionally, the funding will support the development of new genomic technologies and enhancements to existing products, aligning with their strategic goals to improve drug efficacy and accessibility.

## Funding rounds

- Seed, Jun 1, 2011 — Greylock Partners, Third Rock Ventures, Sanofi

## Investors

- Greylock Partners (https://capitalatlas.ai/funds/greylock-partners) — Seed
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Seed
- Sanofi — Seed